91 related articles for article (PubMed ID: 18793341)
1. Increased plasma ghrelin following infliximab in Crohn's disease.
Sung EZ; Da Silva NF; Goodyear S; McTernan PG; Sanger GJ; Nwokolo CU
Aliment Pharmacol Ther; 2009 Jan; 29(1):83-9. PubMed ID: 18793341
[TBL] [Abstract][Full Text] [Related]
2. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
4. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
5. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
6. Infliximab treatment in a patient with Crohn's disease on haemodialysis.
Kume K; Yamasaki M; Yoshikawa I; Harada M
Colorectal Dis; 2011 Mar; 13(3):341. PubMed ID: 20082632
[No Abstract] [Full Text] [Related]
7. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
8. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.
Di Sabatino A; Ciccocioppo R; Benazzato L; Sturniolo GC; Corazza GR
Aliment Pharmacol Ther; 2004 May; 19(9):1019-24. PubMed ID: 15113369
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
Eivindson M; Grønbaek H; Skogstrand K; Thorsen P; Frystyk J; Flyvbjerg A; Dahlerup JF
Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort.
Pittet V; Juillerat P; Michetti P; Vader JP; Burnand B; Rogler G; Beglinger C; Seibold F; Mottet C; Felley C; Gonvers JJ; Froehlich F;
Aliment Pharmacol Ther; 2010 Oct; 32(8):1007-16. PubMed ID: 20937046
[TBL] [Abstract][Full Text] [Related]
11. Infliximab (Remicade), a new biological treatment for Crohn's disease.
D'Haens GR
Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
[TBL] [Abstract][Full Text] [Related]
12. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
13. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
14. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.
Ljung T; Axelsson LG; Herulf M; Lundberg JO; Hellström PM
Aliment Pharmacol Ther; 2007 Apr; 25(8):925-32. PubMed ID: 17402996
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to infliximab in Crohn's disease.
Chaudhary R; Ghosh S
Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
[No Abstract] [Full Text] [Related]
16. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.
Vadan R; Gheorghe LS; Constantinescu A; Gheorghe C
Clin Nutr; 2011 Feb; 30(1):86-91. PubMed ID: 20719413
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.
Waugh AW; Garg S; Matic K; Gramlich L; Wong C; Sadowski DC; Millan M; Bailey R; Todoruk D; Cherry R; Teshima CW; Dieleman L; Fedorak RN
Aliment Pharmacol Ther; 2010 Nov; 32(9):1129-34. PubMed ID: 20807218
[TBL] [Abstract][Full Text] [Related]
19. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
[TBL] [Abstract][Full Text] [Related]
20. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
